ConductScience.org, home
PC-3
API referenceFor AI assistants

Cell line · CVCL_0035

Papers364

2 more articles give this line's RRID in its Methods without naming the line nearby, so they are not listed.

1 to 20 of 364

Download this page as JSON
PaperJournalYearHow we knowRetractedSource
SRSF1 coordinates transcription and alternative splicing to modulate p53 and apoptosis.bioRxiv2026Its Methods give the RRID and name the linePubMed
In vivo validation of intramolecular bivalent glues targeting PSMA reveals potent and tissue-selective BRD4 degradation in prostate cancer.Acta Pharm Sin B2026Its Methods give the RRID and name the linePubMed
Design of Potent, Non-Toxic Antimicrobial Agents Derived from the Frog Skin Peptide Raniseptin-PL Active Against Gram-Negative ESKAPE+ Pathogens.Antibiotics (Basel)2026Its Methods give the RRID and name the linePubMed
Primary tumor-derived lactate primes prostate cancer cells for a dormant fate.Sci Adv2026Its Methods give the RRID and name the linePubMed
Berberine and Etoposide Exert Synergistic Anticancer Effects in A431 Epidermoid Carcinoma Cells.ACS Omega2026Its Methods give the RRID and name the linePubMed
Physicochemical Characterisation and In Vitro Bioactivity of Sumac (Rhus coriaria)-Derived Exosome-Like Nanoparticles.Chem Biodivers2026Its Methods give the RRID and name the linePubMed
Prostate Cancer Patient-Derived Organoids (PDOs) as Functional Avatars for Antisense Oligonucleotide (ASO)-Based Personalized Therapy.Adv Healthc Mater2026Its Methods give the RRID and name the linePubMed
Phytochemical Analysis Using LC-MS/MS and Anticancer Activity of Asphodelus tenuifolius Roots: Cell Cycle Arrest, Apoptosis, and In Silico Insights.Chem Biodivers2026Its Methods give the RRID and name the linePubMed
Combination of PARP inhibitor olaparib and a vascular disrupting agent reduces tumor growth in a preclinical model of prostate cancer.Cancer Chemother Pharmacol2026Its Methods give the RRID and name the linePubMed
Nutrient deprivation enhances the cytotoxic effects of a sulfonamide-chalcone hybrid in PC-3 prostate cancer cells.Mol Cell Biochem2026Its Methods give the RRID and name the linePubMed
Castration-resistant prostate cancer cells are addicted to the high activity of cyclin-dependent kinase 2.Mol Oncol2026Its Methods give the RRID and name the linePubMed
Vitronectin Enrichment in Prostate Cancer Liver Metastases Promotes Adhesion and Survival.Cancer Res Commun2026Its Methods give the RRID and name the linePubMed
Bioactive Properties of Achillea biserrata M.Bieb. Extracts: Phytochemical Analysis, Antioxidant Activity, Target Enzyme Inhibition, and Cytotoxic Effects.Chem Biodivers2026Its Methods give the RRID and name the linePubMed
MYDGF as a telomerase activator and therapeutic target for osteoarthritis.Adv Biotechnol (Singap)2026Its Methods give the RRID and name the linePubMed
Sarcosine-Based Pharmacokinetic Optimization and Fluorescent Dye Library Evaluation of Dual-Labeled PSMA Inhibitors for Fluorescence-Guided Surgery.Pharmaceuticals (Basel)2026Its Methods give the RRID and name the linePubMed
The Laron Syndrome Mouse Model Reveals a Potential Contribution of Methylglyoxal-Derived Glycative Stress to IGF-1-Driven Prostate Cancer Progression.Biology (Basel)2026Its Methods give the RRID and name the linePubMed
CRB-701: A Second-generation Nectin-4-Targeted Antibody-Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors.Cancer Res Commun2026Its Methods give the RRID and name the linePubMed
Scalable generation of hematopoietic stem cell-engineered off-the-shelf mono-specific cytotoxic T cells targeting solid tumors.Cell Rep Med2026Its Methods give the RRID and name the linePubMed
Multi-omics dissection of FOXA1 reveals cancer-type-specific transcriptional networks and functional risk variants.iScience2026Its Methods give the RRID and name the linePubMed
In silico high-throughput screening system for INMT activators in prostate cancer therapy.Front Pharmacol2026Its Methods give the RRID and name the linePubMed

cell-lines-2026-11-14-0.1.0

Next page

Sources 4

  • CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
  • PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
  • NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
  • PubMedNLM's terms
Each source's terms
  • CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
  • PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
  • NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
  • PubMedNLM's terms

Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/cell-lines/v1/CVCL_0035/papers

API referenceFor AI assistants